Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | PHASE1 | COMPLETED | 40 | — | — | Sep 24, 2018 | Aug 18, 2021 | Nov 15, 2021 | 4 | United States |
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.
PAD defined as a dose that achieves a level of receptor occupancy considered to be biologically active.
| Arm | Type | Description |
|---|---|---|
| INCAGN02390 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| INCAGN02390 | DRUG | Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD. |
Inclusion Criteria: * Participants with locally advanced or metastatic tumors who are not eligible for any available therapy likely to convey clinical benefit (locally advanced disease must not be amenable to resection with curative intent). * Participants who have disease progression after treatme...